The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | Recommendations for biomarker analysis in CLL: updates from ERIC 2024
Richard Rosenquist, MD, PhD, Karolinska Institute, Solna, Sweden, shares recommendations for biomarker analysis in chronic lymphocytic leukemia (CLL). He highlights the need to reassess the value of these markers in the era of newer targeted therapies. Additionally, he discusses the evolving methods to assess genomic complexity and the ongoing debate over the best technology for identifying high-risk patients. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: AbbVie, AstraZeneca, Illumina, Janssen and Roche.
